Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
GeneOntologyMolecularFunctionglucuronosyltransferase activity

UGT2B4 UGT2B7 UGT2B10

7.43e-0635223GO:0015020
GeneOntologyMolecularFunctionglycosyltransferase activity

UGT2B4 UGT2B7 UGT2B10 ST6GAL2

2.53e-04288224GO:0016757
GeneOntologyMolecularFunctionretinoic acid binding

UGT2B4 UGT2B7

4.30e-0428222GO:0001972
GeneOntologyMolecularFunctionUDP-glycosyltransferase activity

UGT2B4 UGT2B7 UGT2B10

6.10e-04153223GO:0008194
GeneOntologyMolecularFunctionretinoid binding

UGT2B4 UGT2B7

1.27e-0348222GO:0005501
GeneOntologyMolecularFunctionisoprenoid binding

UGT2B4 UGT2B7

1.32e-0349222GO:0019840
GeneOntologyMolecularFunctionhexosyltransferase activity

UGT2B4 UGT2B7 UGT2B10

1.54e-03211223GO:0016758
GeneOntologyMolecularFunctioncarboxylic acid binding

UGT2B4 UGT2B7 AGRN

2.20e-03239223GO:0031406
GeneOntologyMolecularFunctionorganic acid binding

UGT2B4 UGT2B7 AGRN

2.62e-03254223GO:0043177
GeneOntologyMolecularFunctionmonocarboxylic acid binding

UGT2B4 UGT2B7

6.13e-03107222GO:0033293
GeneOntologyMolecularFunctionlipase activity

ABHD15 PLCG1

1.00e-02138222GO:0016298
GeneOntologyMolecularFunctioncytokine binding

AGRN IFNAR2

1.28e-02157222GO:0019955
GeneOntologyMolecularFunctionimmune receptor activity

FCMR IFNAR2

1.41e-02165222GO:0140375
GeneOntologyMolecularFunctionprotein kinase binding

NFATC1 STK11IP PLCG1 IFNAR2

1.41e-02873224GO:0019901
GeneOntologyBiologicalProcessbiphenyl catabolic process

UGT2B4 UGT2B7 UGT2B10

5.88e-088223GO:0070980
GeneOntologyBiologicalProcessbiphenyl metabolic process

UGT2B4 UGT2B7 UGT2B10

1.26e-0710223GO:0018879
GeneOntologyBiologicalProcessxenobiotic glucuronidation

UGT2B4 UGT2B7 UGT2B10

2.30e-0712223GO:0052697
GeneOntologyBiologicalProcesscellular glucuronidation

UGT2B4 UGT2B7 UGT2B10

1.38e-0621223GO:0052695
GeneOntologyBiologicalProcessglucuronate metabolic process

UGT2B4 UGT2B7 UGT2B10

2.70e-0626223GO:0019585
GeneOntologyBiologicalProcessuronic acid metabolic process

UGT2B4 UGT2B7 UGT2B10

2.70e-0626223GO:0006063
GeneOntologyBiologicalProcessbenzene-containing compound metabolic process

UGT2B4 UGT2B7 UGT2B10

7.99e-0637223GO:0042537
GeneOntologyBiologicalProcessxenobiotic catabolic process

UGT2B4 UGT2B7 UGT2B10

7.99e-0637223GO:0042178
GeneOntologyBiologicalProcessandrogen metabolic process

UGT2B4 UGT2B7 UGT2B10

8.67e-0638223GO:0008209
GeneOntologyBiologicalProcessestrogen metabolic process

UGT2B4 UGT2B7 UGT2B10

2.25e-0552223GO:0008210
GeneOntologyBiologicalProcesscellular catabolic process

UGT2B4 UGT2B7 UGT2B10 CYP39A1 BCKDHB PLCG1 EPG5

2.28e-041253227GO:0044248
GeneOntologyBiologicalProcessxenobiotic metabolic process

UGT2B4 UGT2B7 UGT2B10

4.38e-04141223GO:0006805
GeneOntologyBiologicalProcesscarboxylic acid metabolic process

UGT2B4 UGT2B7 UGT2B10 CYP39A1 ST6GAL2 BCKDHB

5.87e-041035226GO:0019752
GeneOntologyBiologicalProcesssteroid metabolic process

UGT2B4 UGT2B7 UGT2B10 CYP39A1

6.13e-04376224GO:0008202
GeneOntologyBiologicalProcessoxoacid metabolic process

UGT2B4 UGT2B7 UGT2B10 CYP39A1 ST6GAL2 BCKDHB

6.59e-041058226GO:0043436
GeneOntologyBiologicalProcessorganic acid metabolic process

UGT2B4 UGT2B7 UGT2B10 CYP39A1 ST6GAL2 BCKDHB

6.79e-041064226GO:0006082
GeneOntologyCellularComponentnuclear outer membrane

UGT2B4 UGT2B7 UGT2B10

9.75e-0640223GO:0005640
DomainUDPGT

UGT2B4 UGT2B7 UGT2B10

1.61e-0621213PS00375
DomainUDPGT

UGT2B4 UGT2B7 UGT2B10

1.61e-0621213PF00201
DomainUDP_glucos_trans

UGT2B4 UGT2B7 UGT2B10

1.61e-0621213IPR002213
DomainPH

PLEKHH1 PLCG1 GRK3

2.06e-03229213PF00169
DomainPH

PLEKHH1 PLCG1 GRK3

3.56e-03278213SM00233
DomainPH_DOMAIN

PLEKHH1 PLCG1 GRK3

3.59e-03279213PS50003
DomainPH_domain

PLEKHH1 PLCG1 GRK3

3.63e-03280213IPR001849
Domain-

PLEKHH1 PLCG1 GRK3

9.15e-033912132.30.29.30
DomainPH_dom-like

PLEKHH1 PLCG1 GRK3

1.15e-02426213IPR011993
DomainSH3_1

SH3TC2 PLCG1

1.44e-02164212PF00018
DomainEF_Hand_1_Ca_BS

CAPN14 PLCG1

1.63e-02175212IPR018247
PathwayREACTOME_PREDNISONE_ADME

UGT2B4 UGT2B7 UGT2B10

3.61e-0623193MM16639
PathwayREACTOME_GLUCURONIDATION

UGT2B4 UGT2B7 UGT2B10

4.13e-0624193MM14599
PathwayREACTOME_GLUCURONIDATION

UGT2B4 UGT2B7 UGT2B10

4.69e-0625193M17787
PathwayWP_GLUCURONIDATION

UGT2B4 UGT2B7 UGT2B10

4.69e-0625193MM15820
PathwayKEGG_ASCORBATE_AND_ALDARATE_METABOLISM

UGT2B4 UGT2B7 UGT2B10

4.69e-0625193M605
PathwayWP_GLUCURONIDATION

UGT2B4 UGT2B7 UGT2B10

5.29e-0626193M39404
PathwayKEGG_PENTOSE_AND_GLUCURONATE_INTERCONVERSIONS

UGT2B4 UGT2B7 UGT2B10

6.66e-0628193M19580
PathwayREACTOME_PARACETAMOL_ADME

UGT2B4 UGT2B7 UGT2B10

1.84e-0539193MM15695
PathwayKEGG_PORPHYRIN_AND_CHLOROPHYLL_METABOLISM

UGT2B4 UGT2B7 UGT2B10

2.14e-0541193M7399
PathwayREACTOME_ASPIRIN_ADME

UGT2B4 UGT2B7 UGT2B10

2.65e-0544193M45014
PathwayREACTOME_ASPIRIN_ADME

UGT2B4 UGT2B7 UGT2B10

2.84e-0545193MM15694
PathwayKEGG_DRUG_METABOLISM_OTHER_ENZYMES

UGT2B4 UGT2B7 UGT2B10

4.15e-0551193M17726
PathwayKEGG_STARCH_AND_SUCROSE_METABOLISM

UGT2B4 UGT2B7 UGT2B10

4.40e-0552193M14171
PathwayKEGG_STEROID_HORMONE_BIOSYNTHESIS

UGT2B4 UGT2B7 UGT2B10

5.21e-0555193M14933
PathwayKEGG_RETINOL_METABOLISM

UGT2B4 UGT2B7 UGT2B10

8.21e-0564193M9488
PathwayKEGG_METABOLISM_OF_XENOBIOTICS_BY_CYTOCHROME_P450

UGT2B4 UGT2B7 UGT2B10

1.07e-0470193M16794
PathwayKEGG_DRUG_METABOLISM_CYTOCHROME_P450

UGT2B4 UGT2B7 UGT2B10

1.17e-0472193M9257
PathwayWP_CODEINE_AND_MORPHINE_METABOLISM

UGT2B4 UGT2B7

1.55e-0414192M39328
PathwayREACTOME_BIOLOGICAL_OXIDATIONS

UGT2B4 UGT2B7 UGT2B10 CYP39A1

1.83e-04219194MM14838
PathwayREACTOME_BIOLOGICAL_OXIDATIONS

UGT2B4 UGT2B7 UGT2B10 CYP39A1

1.86e-04220194M10320
PathwayKEGG_MEDICUS_REFERENCE_EGF_EGFR_PLCG_CALCINEURIN_SIGNALING_PATHWAY

NFATC1 PLCG1

2.04e-0416192M47449
PathwayWP_TCELL_ACTIVATION_SARSCOV2

NFATC1 PLCG1 IFNAR2

2.12e-0488193M42580
PathwayKEGG_MEDICUS_PATHOGEN_HIV_GP120_TO_CXCR4_GNAQ_PLCB_G_CALCINEURIN

NFATC1 PLCG1

2.31e-0417192M47560
PathwayBIOCARTA_CALCINEURIN_PATHWAY

NFATC1 PLCG1

2.60e-0418192M3430
PathwayBIOCARTA_CALCINEURIN_PATHWAY

NFATC1 PLCG1

2.60e-0418192MM1385
PathwayKEGG_MEDICUS_REFERENCE_CXCR4_GNAQ_PLCB_G_CALCINEURIN_SIGNALING_PATHWAY

NFATC1 PLCG1

3.56e-0421192M47542
PathwayREACTOME_PHASE_II_CONJUGATION_OF_COMPOUNDS

UGT2B4 UGT2B7 UGT2B10

3.77e-04107193MM14595
PathwayREACTOME_DRUG_ADME

UGT2B4 UGT2B7 UGT2B10

3.98e-04109193M45012
PathwayREACTOME_PHASE_II_CONJUGATION_OF_COMPOUNDS

UGT2B4 UGT2B7 UGT2B10

3.98e-04109193M18788
PathwayBIOCARTA_VIP_PATHWAY

NFATC1 PLCG1

5.07e-0425192MM1441
PathwayREACTOME_DRUG_ADME

UGT2B4 UGT2B7 UGT2B10

5.15e-04119193MM15692
PathwayBIOCARTA_VIP_PATHWAY

NFATC1 PLCG1

5.49e-0426192M17941
PathwayBIOCARTA_GPCR_PATHWAY

NFATC1 PLCG1

6.84e-0429192MM1495
PathwayBIOCARTA_GPCR_PATHWAY

NFATC1 PLCG1

7.32e-0430192M9664
PathwayKEGG_NATURAL_KILLER_CELL_MEDIATED_CYTOTOXICITY

NFATC1 PLCG1 IFNAR2

7.76e-04137193M5669
PathwayBIOCARTA_BCR_PATHWAY

NFATC1 PLCG1

8.33e-0432192MM1355
PathwayBIOCARTA_BCR_PATHWAY

NFATC1 PLCG1

8.86e-0433192M9494
PathwayBIOCARTA_FCER1_PATHWAY

NFATC1 PLCG1

1.24e-0339192M1908
PathwayBIOCARTA_FCER1_PATHWAY

NFATC1 PLCG1

1.24e-0339192MM1397
PathwayBIOCARTA_TCR_PATHWAY

NFATC1 PLCG1

1.43e-0342192MM1504
PathwayBIOCARTA_TCR_PATHWAY

NFATC1 PLCG1

1.57e-0344192M19784
PathwayWP_METAPATHWAY_BIOTRANSFORMATION_PHASE_I_AND_II

UGT2B4 UGT2B7 CYP39A1

1.79e-03183193M39588
PathwayWP_RANKLRANK_SIGNALING

NFATC1 PLCG1

2.45e-0355192M39667
PathwayREACTOME_FCERI_MEDIATED_CA_2_MOBILIZATION

NFATC1 PLCG1

2.72e-0358192MM14914
PathwayPID_CD8_TCR_DOWNSTREAM_PATHWAY

NFATC1 IFNAR2

3.40e-0365192M272
PathwayWP_TH17_CELL_DIFFERENTIATION_PATHWAY

NFATC1 PLCG1

3.83e-0369192M45541
PathwayWP_PRIMARY_FOCAL_SEGMENTAL_GLOMERULOSCLEROSIS_FSGS

AGRN PLCG1

4.16e-0372192M39403
PathwayWP_PRIMARY_FOCAL_SEGMENTAL_GLOMERULOSCLEROSIS_FSGS

AGRN PLCG1

4.27e-0373192MM15906
Pubmed

Weak activity of UDP-glucuronosyltransferase toward Bisphenol analogs in mouse perinatal development.

UGT2B4 UGT2B7 UGT2B10

7.68e-09722326074487
Pubmed

Hetero-oligomer formation of mouse UDP-glucuronosyltransferase (UGT) 2b1 and 1a1 results in the gain of glucuronidation activity towards morphine, an activity which is absent in homo-oligomers of either UGT.

UGT2B4 UGT2B7 UGT2B10

1.23e-08822332093886
Pubmed

Polymorphic gene regulation and interindividual variation of UDP-glucuronosyltransferase activity in human small intestine.

UGT2B4 UGT2B7 UGT2B10

1.23e-08822310748067
Pubmed

Substrate specificity of the human UDP-glucuronosyltransferase UGT2B4 and UGT2B7. Identification of a critical aromatic amino acid residue at position 33.

UGT2B4 UGT2B7

3.82e-07222217263731
Pubmed

Single nucleotide polymorphisms and haplotype frequencies of UGT2B4 and UGT2B7 in a Japanese population.

UGT2B4 UGT2B7

3.82e-07222215319348
Pubmed

Expression of UDP-glucuronosyltransferases (UGTs) 2B7 and 1A6 in the human brain and identification of 5-hydroxytryptamine as a substrate.

UGT2B4 UGT2B7

3.82e-07222210222050
Pubmed

Isolation of a human YAC contig encompassing a cluster of UGT2 genes and its regional localization to chromosome 4q13.

UGT2B4 UGT2B7

1.15e-0632227835904
Pubmed

cDNA cloning and expression of two new members of the human liver UDP-glucuronosyltransferase 2B subfamily.

UGT2B4 UGT2B10

1.15e-0632228333863
Pubmed

Methadone inhibits CYP2D6 and UGT2B7/2B4 in vivo: a study using codeine in methadone- and buprenorphine-maintained subjects.

UGT2B4 UGT2B7

1.15e-06322222092298
Pubmed

Clopidogrel Carboxylic Acid Glucuronidation is Mediated Mainly by UGT2B7, UGT2B4, and UGT2B17: Implications for Pharmacogenetics and Drug-Drug Interactions .

UGT2B4 UGT2B7

1.15e-06322229138287
Pubmed

Contribution of polymorphisms in UDP-glucuronosyltransferase and CYP2D6 to the individual variation in disposition of carvedilol.

UGT2B4 UGT2B7

2.29e-06422216849011
Pubmed

Lyn inhibits osteoclast differentiation by interfering with PLCgamma1-mediated Ca2+ signaling.

NFATC1 PLCG1

2.29e-06422219285079
Pubmed

Regulation and function of family 1 and family 2 UDP-glucuronosyltransferase genes (UGT1A, UGT2B) in human oesophagus.

UGT2B7 UGT2B10

2.29e-06422210024527
Pubmed

UDP-glucuronosyltransferase and sulfotransferase polymorphisms, sex hormone concentrations, and tumor receptor status in breast cancer patients.

UGT2B4 UGT2B7

3.82e-06522215318931
Pubmed

Disposition of flavonoids via enteric recycling: enzyme stability affects characterization of prunetin glucuronidation across species, organs, and UGT isoforms.

UGT2B4 UGT2B7

1.07e-05822218052087
Pubmed

The configuration of the 17-hydroxy group variably influences the glucuronidation of beta-estradiol and epiestradiol by human UDP-glucuronosyltransferases.

UGT2B4 UGT2B7

1.07e-05822218719240
Pubmed

Associations between polymorphisms in glucuronidation and sulfation enzymes and mammographic breast density in premenopausal women in the United States.

UGT2B4 UGT2B7

1.07e-05822220142249
Pubmed

Detoxification enzyme polymorphisms are not involved in duodenal adenomatosis in familial adenomatous polyposis.

UGT2B4 UGT2B7

2.51e-051222218161889
Pubmed

Role of UDP-glucuronosyltransferase isoforms in 13-cis retinoic acid metabolism in humans.

UGT2B4 UGT2B7

2.51e-051222220308471
Pubmed

Phase II metabolism of hesperetin by individual UDP-glucuronosyltransferases and sulfotransferases and rat and human tissue samples.

UGT2B4 UGT2B7

5.81e-051822220056724
Pubmed

Biological pathway-based genome-wide association analysis identified the vasoactive intestinal peptide (VIP) pathway important for obesity.

NFATC1 PLCG1

9.59e-052322220379146
Pubmed

T-Cell Signaling in HIV-1 Infection.

NFATC1 PLCG1

1.87e-043222223986795
Pubmed

Signaling pathways triggered by HIV-1 Tat in human monocytes to induce TNF-alpha.

NFATC1 PLCG1

2.65e-043822212482669
Pubmed

Identification of transcripts with enriched expression in the developing and adult pancreas.

UGT2B4 UGT2B7 UGT2B10 GRK3

5.81e-0462422418554416
Cytoband4q13

UGT2B4 UGT2B7

2.29e-05152224q13
CytobandEnsembl 112 genes in cytogenetic band chr4q13

UGT2B4 UGT2B7 UGT2B10

5.76e-05157223chr4q13
GeneFamilyUDP glucuronosyltransferases

UGT2B4 UGT2B7 UGT2B10

3.37e-0632173363
GeneFamilyPleckstrin homology domain containing|Rho guanine nucleotide exchange factors|C2 domain containing

PLEKHH1 PLCG1 GRK3

8.81e-04206173682
GeneFamilyEF-hand domain containing

CAPN14 PLCG1

1.76e-02219172863
CoexpressionWENG_POR_TARGETS_LIVER_UP

UGT2B4 UGT2B7 UGT2B10

1.17e-0553223MM1203
CoexpressionVANLOO_SP3_TARGETS_DN

UGT2B4 UGT2B7 UGT2B10

8.60e-05103223MM919
CoexpressionSERVITJA_ISLET_HNF1A_TARGETS_DN

UGT2B4 UGT2B7 UGT2B10

1.39e-04121223MM935
CoexpressionSOBOLEV_T_CELL_PANDEMRIX_AGE_18_64YO_7DY_DN

NFATC1 PLCG1

1.40e-0421222M41206
CoexpressionSHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM4

UGT2B4 UGT2B7 UGT2B10 ABHD15

1.51e-04330224MM1120
CoexpressionSOBOLEV_T_CELL_PANDEMRIX_AGE_18_64YO_1DY_UP

NFATC1 PLCG1

1.68e-0423222M41207
ToppCellSmart-seq2-tissue-resident_(Smart-seq2)-myeloid-myeloid_monocytic-non-classical_monocyte|tissue-resident_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type

STK11IP SLITRK4 GRK3

2.96e-051232232a5e3c579f4b390c0a0d6d81c0a94c1b00dcbd85
ToppCelldroplet-Heart-nan-24m-Hematologic-coronary_vascular_endothelial_cell|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

PLEKHH1 DENND3 PLCG1

7.34e-05167223bad33497ceeab968a7eb8a48b921c6f936390743
ToppCell343B-Fibroblasts-Fibroblast-H-|Fibroblasts / Donor, Lineage, Cell class and subclass (all cells)

UGT2B4 PLEKHH1 ABHD15

8.01e-05172223709c6b77a7a52b873eefb6caca28a41291d384af
ToppCell343B-Fibroblasts-Fibroblast-H|Fibroblasts / Donor, Lineage, Cell class and subclass (all cells)

UGT2B4 PLEKHH1 ABHD15

8.01e-05172223eb199c279fe8a2551121db37e9556893197d33ff
ToppCelldroplet-Lung-30m-Hematologic-myeloid-Basophil/Mast_cell-basophil_l26|30m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype

KIAA2012 ABHD15 TACR1

8.29e-05174223009e88a6c79689a5d88b0af50aa89aa03b33f800
ToppCelldroplet-Lung-30m-Hematologic-myeloid-Basophil/Mast_cell|30m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype

KIAA2012 ABHD15 TACR1

8.29e-05174223e9e4532a474b4b0938a50ff85c9508aca53cd3ae
ToppCellCOVID-19-kidney-Bcells|kidney / Disease (COVID-19 only), tissue and cell type

NFATC1 GRK3 FCMR

9.17e-051802235650fc7ebcdf5e0be9a217a58d36a8386d59fd1b
ToppCellrenal_cortex_nuclei-Adult_normal_reference-Immune-Lymphocytic_B|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

NFATC1 GRK3 FCMR

9.17e-0518022365c069585737302a69b9a01476f4eb8b50cb2bfd
ToppCell10x5'-bone_marrow-Mast-Mast_cell_lympho|bone_marrow / Manually curated celltypes from each tissue

STK11IP ABHD15 DENND3

9.32e-0518122356fa77ae31f3b7de6e441a439c33a11353b6573a
ToppCell3'-Child09-12-SmallIntestine-Hematopoietic-B_cells-FCRL4+_Memory_B|Child09-12 / Celltypes from developing, pediatric, Crohn's, & adult GI tract

UGT2B4 GRK3 FCMR

9.79e-0518422395cf125127658c4c04445c61809d1aed21ee1f83
ToppCellrenal_cortex_nuclei-Adult_normal_reference-Immune-Lymphocytic_B-B_Cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

NFATC1 GRK3 FCMR

1.03e-04187223edad646d5eb1d70b768dc21fe02ef5265214e8e6
ToppCellrenal_cortex_nuclei-Adult_normal_reference-Immune-Lymphocytic_B-B_Cell-|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

NFATC1 GRK3 FCMR

1.03e-041872238fa454dc4e6a3e8e2bb2ad803acc579e0d3f76da
ToppCell10x_3'_v3-tissue-resident_(10x_3'_v3)-hematologic|tissue-resident_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type

UGT2B4 UGT2B7 UGT2B10

1.03e-04187223edb0ab0154542b1c0b3a2c216c4a60f0f06290b3
ToppCellSmart-seq2-blood_(Smart-seq2)-lymphocytic-B_lymphocytic-naive_B_cell|blood_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type

NFATC1 GRK3 FCMR

1.03e-04187223160e5f338537d90d50f863a1be801b1071ac7da7
ToppCell10x_3'_v3-tissue-resident_(10x_3'_v3)-hematologic-erythrocytic|tissue-resident_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type

UGT2B4 UGT2B7 UGT2B10

1.06e-041892237899af78b273d9c7f029d52f7e0cf6df4da41f5e
ToppCell10x_3'_v3-tissue-resident_(10x_3'_v3)-hematologic-erythrocytic-erythrocyte|tissue-resident_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type

UGT2B4 UGT2B7 UGT2B10

1.08e-04190223a34293601aefe5fb5c400c14091294b9ddaa195b
ToppCellcritical-Lymphoid-B_cell|Lymphoid / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls

DENND3 GRK3 FCMR

1.14e-04194223eeae611ab72d602fb545c729a14ef38ce5c47f2c
ToppCellControl-Myeloid-ncMonocyte|World / Disease state, Lineage and Cell class

DENND3 GRK3 IFNAR2

1.16e-04195223b4444b67a709e82b8e2ee510924c3152cb88b051
ToppCell(7)_Epithelial_cells-(7)_Epithelial-I_(AT1)|(7)_Epithelial_cells / Lung cell shreds - cell class (v4) and cell subclass (v4)

AGRN ST6GAL2 DENND3

1.23e-041992235a002d49a8b84c158f7b4d7a3e78e6a937757bb7
ToppCellbackground-Hepatocytes|World / Sample and Cell Type and Tumor Cluster (all cells)

UGT2B4 UGT2B7 UGT2B10

1.25e-04200223423cca10df6ae0489a8fe7e7df87e70364dac022
ComputationalSteroid hormone and heme metabolism.

UGT2B4 UGT2B7 UGT2B10

5.91e-0716123MODULE_505
ComputationalGenes in the cancer module 227.

UGT2B4 UGT2B7

1.19e-0415122MODULE_227
Drug7-hydroxycoumarin glucuronide

UGT2B4 UGT2B7 UGT2B10 CYP39A1

1.25e-0829214CID000125641
Drug2-hydroxyestriol

UGT2B4 UGT2B7 UGT2B10

1.35e-086213CID000014688
DrugBP-3,6-quinol

UGT2B4 UGT2B7 UGT2B10 CYP39A1

2.15e-0833214CID000119292
Drug7-methoxycoumarin

UGT2B4 UGT2B7 UGT2B10 CYP39A1

2.05e-0757214CID000010748
Drug4-hydroxybiphenyl

UGT2B4 UGT2B7 UGT2B10 CYP39A1

2.35e-0759214CID000007103
Drug3-OHBaP

UGT2B4 UGT2B7 UGT2B10 CYP39A1

3.07e-0763214CID000025890
Drugmethoxyresorufin

UGT2B4 UGT2B7 UGT2B10 CYP39A1

4.45e-0769214CID000119220
DrugC1 11-32

UGT2B4 UGT2B7 UGT2B10

5.47e-0718213CID000443077
DrugC11131

UGT2B4 UGT2B7 UGT2B10

5.47e-0718213CID000443076
Drug7-hydroxycoumarin

UGT2B4 UGT2B7 UGT2B10 CYP39A1

6.23e-0775214CID005281426
DrugT4-G

UGT2B4 UGT2B7 UGT2B10

6.49e-0719213CID000152424
Drugbenzyloxyresorufin

UGT2B4 UGT2B7 UGT2B10 CYP39A1

7.30e-0778214CID000114982
DrugN'-nitrosoanatabine

UGT2B4 UGT2B7 UGT2B10

7.63e-0720213CID000051291
Drugestriol-16-glucuronide

UGT2B4 UGT2B7 UGT2B10

8.90e-0721213CID000122281
DrugN'-nitrosoanabasine

UGT2B4 UGT2B7 UGT2B10

1.03e-0622213CID000014335
Drug7-ethoxycoumarin

UGT2B4 UGT2B7 UGT2B10 CYP39A1

1.08e-0686214CID000035703
Drugpentoxyresorufin

UGT2B4 UGT2B7 UGT2B10 CYP39A1

1.13e-0687214CID000107683
Drugestradiol-3-glucuronide

UGT2B4 UGT2B7 UGT2B10

1.18e-0623213CID000066651
Drugp-nitroanisole

UGT2B4 UGT2B7 UGT2B10 CYP39A1

1.42e-0692214CID000007485
Drugethoxyresorufin

UGT2B4 UGT2B7 UGT2B10 CYP39A1

1.61e-0695214CID000003294
DrugDCNB

UGT2B4 UGT2B7 UGT2B10 CYP39A1

1.61e-0695214CID000007443
Drug1-naphthol

UGT2B4 UGT2B7 UGT2B10 CYP39A1

1.83e-0698214CID000007005
Drug3 -hydroxypregn-5-en-20-one

UGT2B4 UGT2B7 UGT2B10 CYP39A1 GRK3

2.12e-06238215CID000001027
DrugL-idaro-1,4-lactone

UGT2B4 UGT2B7 UGT2B10

2.18e-0628213CID000078997
Drug5 alpha-dihydroaldosterone

UGT2B4 UGT2B7

2.43e-063212CID003036614
DrugNNAL

UGT2B4 UGT2B7 UGT2B10

3.30e-0632213CID000104856
Drugmorphine hydrochloride

UGT2B4 UGT2B7 UGT2B10 TACR1 PLCG1 GRK3

3.57e-06481216CID000004253
DrugAC1Q6OQG

UGT2B4 UGT2B7 UGT2B10

3.62e-0633213CID000009686
DrugAC1Q7AUJ

UGT2B4 UGT2B7 UGT2B10 CYP39A1

3.70e-06117214CID000003303
Drugfibrates

UGT2B4 UGT2B7 UGT2B10 BCKDHB

3.83e-06118214CID000002797
Drugalpha-naphthoflavone

UGT2B4 UGT2B7 UGT2B10 CYP39A1

3.83e-06118214CID000011790
Drugbenzphetamine

UGT2B4 UGT2B7 UGT2B10 CYP39A1

3.96e-06119214CID000002341
DrugAC1NOWCJ

UGT2B4 UGT2B7 UGT2B10

4.34e-0635213CID005120112
Drug3-[(3S,5R,10S,13R,14S,17R)-3-[(2S,4R,5R,6S)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-14-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one

UGT2B4 UGT2B7 UGT2B10

4.34e-0635213CID010436171
Drugestrone-3-glucuronide

UGT2B4 UGT2B7 UGT2B10

4.34e-0635213CID000115255
Drughexobarbital

UGT2B4 UGT2B7 UGT2B10 CYP39A1

5.13e-06127214CID000003608
Drugl-borneol

UGT2B4 UGT2B7 UGT2B10

5.15e-0637213CID000010049
Drugharmol

UGT2B4 UGT2B7 UGT2B10

6.54e-0640213CID000068094
Drug2-AF

UGT2B4 UGT2B7 UGT2B10

7.05e-0641213CID000005800
Drugtestosterone glucuronide

UGT2B4 UGT2B7 UGT2B10

7.05e-0641213CID000108192
DrugPTBP

UGT2B4 UGT2B7 UGT2B10

7.59e-0642213CID000007393
Drugclofibrate

UGT2B4 UGT2B7 UGT2B10 CYP39A1 BCKDHB

7.83e-06311215CID000002796
Druganiline

UGT2B4 UGT2B7 UGT2B10 CYP39A1

7.99e-06142214CID000006115
Drugphenolphthalin

UGT2B4 UGT2B7

8.09e-065212CID000066494
Drughyodeoxycholic acid

UGT2B4 UGT2B7

8.09e-065212ctd:C010471
DrugAmobarbital

UGT2B4 UGT2B7

8.09e-065212ctd:D000654
Drugandrosterone glucuronide

UGT2B4 UGT2B7 UGT2B10

8.15e-0643213CID000114833
Drug7,8-benzoquinoline

UGT2B4 UGT2B7 UGT2B10

8.15e-0643213CID000009191
Drug2 E1

UGT2B4 UGT2B7 UGT2B10 CYP39A1

8.68e-06145214CID006102788
DrugMS-222

UGT2B4 UGT2B7 UGT2B10

8.74e-0644213CID000011400
Drugsalicylamide

UGT2B4 UGT2B7 UGT2B10

1.14e-0548213CID000005147
Drug4-(methylnitrosamino)-1-(3-pyridyl)-1-butan-1-ol

UGT2B7 UGT2B10

1.21e-056212ctd:C475721
Drug4-((methylnitrosoamino)-1-(3-pyridyl)but-1-yl)beta-omega-glucosiduronic acid

UGT2B7 UGT2B10

1.21e-056212ctd:C099564
DrugAC1NQGK1

UGT2B4 UGT2B7 UGT2B10

1.45e-0552213CID005195977
Drugoxazepam

UGT2B4 UGT2B7 UGT2B10

1.54e-0553213CID000004616
Drugaminopyrine

UGT2B4 UGT2B7 UGT2B10 CYP39A1

1.66e-05171214CID000006009
Drugoxazepam glucuronide

UGT2B4 UGT2B7

1.70e-057212CID000160870
Drugranirestat

UGT2B4 UGT2B7

1.70e-057212ctd:C115070
Drug4-nitrophenol

UGT2B4 UGT2B7 UGT2B10 CYP39A1

1.91e-05177214CID000000980
Drugphenolphthalein

UGT2B4 UGT2B7 UGT2B10

2.02e-0558213CID000004764
Drugurochloralic acid

UGT2B4 UGT2B7 UGT2B10

2.13e-0559213CID003036914
Drug4-hydroxyestrone

UGT2B4 UGT2B7 UGT2B10

2.13e-0559213CID000018418
DrugSN-38G

UGT2B4 UGT2B7 UGT2B10

2.13e-0559213CID000443154
Drugacetaminophen glucuronide

UGT2B4 UGT2B7 UGT2B10

2.13e-0559213CID000083944
DrugUDP-alpha-d-xylopyranose

UGT2B4 UGT2B7 UGT2B10

2.24e-0560213CID000001165
DrugDNCB

UGT2B4 UGT2B7 UGT2B10 CYP39A1

2.46e-05189214CID000000006
Druganethole trithione

UGT2B4 UGT2B7 UGT2B10

2.59e-0563213CID000002194
DrugN'-nitrosonornicotine

UGT2B4 UGT2B7 UGT2B10

2.59e-0563213CID000027919
DrugPhenethicillin potassium salt [132-93-4]; Down 200; 10uM; PC3; HT_HG-U133A

CYP39A1 BCKDHB PLCG1 GRK3

2.79e-051952145763_DN
DrugSulfachloropyridazine [80-32-0]; Down 200; 14uM; PC3; HT_HG-U133A

CYP39A1 AGRN PLCG1 GRK3

2.79e-051952144326_DN
DrugDicumarol [66-76-2]; Down 200; 11.8uM; PC3; HT_HG-U133A

CYP39A1 DENND3 BCKDHB GRK3

2.84e-051962143766_DN
DrugSpiramycin [8025-81-8]; Down 200; 4.8uM; PC3; HT_HG-U133A

DENND3 PLCG1 GRK3 IFNAR2

2.84e-051962143762_DN
Drugdimethylnitrosamine

UGT2B4 UGT2B7 UGT2B10 CYP39A1

2.84e-05196214CID000006124
DrugGabazine [105538-73-6]; Down 200; 10.8uM; PC3; HT_HG-U133A

CYP39A1 AGRN DENND3 GRK3

2.84e-051962144236_DN
DrugIfosfamide [3778-73-2]; Up 200; 15.4uM; PC3; HT_HG-U133A

CYP39A1 DENND3 TACR1 GRK3

2.96e-051982145805_UP
DrugSuloctidil [54063-56-8]; Down 200; 11.8uM; MCF7; HT_HG-U133A

BCKDHB PLCG1 FCMR IFNAR2

2.96e-051982142651_DN
DrugMethimazole [60-56-0]; Down 200; 35uM; PC3; HT_HG-U133A

DENND3 PLCG1 GRK3 IFNAR2

2.96e-051982144550_DN
Drug15(S)-15-methyl Prostaglandin E2; Down 200; 10uM; PC3; HT_HG-U133A

SH3TC2 DENND3 BCKDHB PLCG1

2.96e-051982147526_DN
Drugbeta-naphthoflavone

UGT2B4 UGT2B7 UGT2B10 CYP39A1

3.08e-05200214CID000002361
DrugMeldola

UGT2B4 UGT2B7 UGT2B10

3.26e-0568213CID000081507
Drugnitrosamine

UGT2B4 UGT2B7 UGT2B10

3.56e-0570213CID000037183
Drugdiclofenac

UGT2B4 UGT2B7 UGT2B10 CYP39A1

3.65e-05209214CID000003032
DrugAroclor 1254

UGT2B4 UGT2B7 UGT2B10 CYP39A1

3.93e-05213214CID000040470
Drug2,2,2-trichloroethanol

UGT2B4 UGT2B7 UGT2B10

4.03e-0573213CID000008259
Drugeugenol

UGT2B4 UGT2B7 UGT2B10

4.03e-0573213CID000003314
Drug1,4-benzodiazepine

UGT2B4 UGT2B7

4.43e-0511212CID000148431
Drugzomepirac

UGT2B4 UGT2B7

4.43e-0511212CID000005733
Drug16-epiestriol

UGT2B4 UGT2B7 UGT2B10

4.73e-0577213CID000003269
DrugAC1N8H7N

UGT2B4 UGT2B7 UGT2B10

4.92e-0578213CID004318740
DrugAC1L1BH2

UGT2B4 UGT2B7 UGT2B10

4.92e-0578213CID000001436
Drug3-methylcholanthrene

UGT2B4 UGT2B7 UGT2B10 CYP39A1

5.40e-05231214CID000001674
Drugacridine

UGT2B4 UGT2B7 UGT2B10

5.51e-0581213CID000009215
Drug1zz2

UGT2B4 UGT2B10 AGRN

5.71e-0582213CID005287728
Drug5 alpha-androstane

UGT2B4 UGT2B7 UGT2B10

6.14e-0584213CID000094144
Drugcotinine-N-glucuronide

UGT2B7 UGT2B10

6.28e-0513212CID000000411
Drugmenthol

UGT2B4 UGT2B7 UGT2B10

6.82e-0587213CID000001254
Drugtiaprofenic acid

UGT2B4 UGT2B7

7.32e-0514212CID000005468
Drugpropranolol glucuronide

UGT2B4 UGT2B7

7.32e-0514212CID000119515
Drug4-aminobiphenyl

UGT2B4 UGT2B7 UGT2B10

8.06e-0592213CID000007102
Drug2-naphthol

UGT2B4 UGT2B7 UGT2B10

8.32e-0593213CID000008663
Diseaseplasma clozapine-to-N-desmethylclozapine ratio measurement

UGT2B4 UGT2B7 UGT2B10

2.60e-089213EFO_0600040
Diseasevanillylmandelate (VMA) measurement

UGT2B4 UGT2B10

1.01e-057212EFO_0800119
Diseasedeoxycholic acid glucuronide measurement

UGT2B7 UGT2B10

1.35e-058212EFO_0800575
DiseaseX-19141 measurement

UGT2B4 UGT2B7

3.75e-0513212EFO_0800799
DiseaseX-24947 measurement

UGT2B4 UGT2B7

1.10e-0422212EFO_0800910
Diseasetestosterone measurement

UGT2B4 UGT2B7 NFATC1 UGT2B10 PLCG1 IFNAR2

1.99e-041275216EFO_0004908
Diseasevitamin D deficiency

UGT2B4 UGT2B7

3.16e-0437212EFO_0003762
Diseasevitamin D measurement, COVID-19

UGT2B4 UGT2B7

5.56e-0449212EFO_0004631, MONDO_0100096
Diseasedisease progression measurement

UGT2B4 UGT2B7

8.61e-0461212EFO_0008336
DiseaseManic Disorder

TACR1 GRK3

1.16e-0371212C0024713
DiseaseManic

TACR1 GRK3

1.40e-0378212C0338831
DiseaseDepression, Bipolar

TACR1 GRK3

1.44e-0379212C0005587
Diseasevitamin D measurement

UGT2B4 UGT2B7 UGT2B10

1.67e-03336213EFO_0004631
Diseasepursuit maintenance gain measurement

TACR1 EPG5

3.44e-03123212EFO_0008433
Diseaseserum gamma-glutamyl transferase measurement

UGT2B4 UGT2B7 UGT2B10 PLCG1

3.59e-03914214EFO_0004532
Diseaseacylcarnitine measurement

NFATC1 FCMR

3.66e-03127212EFO_0005059
DiseaseBipolar Disorder

TACR1 PLCG1 GRK3

4.50e-03477213C0005586
Diseasemetabolite measurement

UGT2B4 UGT2B7 UGT2B10

7.01e-03560213EFO_0004725
DiseaseHMG CoA reductase inhibitor use measurement

UGT2B7 UGT2B10

7.91e-03189212EFO_0009932

Protein segments in the cluster

PeptideGeneStartEntry
IWQKFFLLYLHRPGP

EPG5

1311

Q9HCE0
VDWQHVYLQKYPPPL

GRK3

456

P35626
FVNPAPPYLWPAHKN

AGRN

116

O00468
YLYPLQWQHPFVPIL

DENND3

236

A2RUS2
LPWPYERGFLLHQKI

ABHD15

276

Q6UXT9
WKRPPELHSNPQFYF

CAPN14

71

A8MX76
PFPHIFEPFYIPDKW

BCKDHB

366

P21953
YLAVPQHPYQWAKPK

NFATC1

386

O95644
PPKYHLLPVFPSFWI

KIAA2012

206

Q0VF49
NFHNFLAWPFPNLPP

IFNAR2

281

P48551
WLHRNPKYFPEPELF

CYP39A1

371

Q9NYL5
LRKLYLEGNPLWFHP

STK11IP

281

Q8N1F8
PNQLKPPWSNFYHLN

SLITRK4

51

Q8IW52
WLPFHIFFLLPYINP

TACR1

261

P25103
NPNQPFYILHPKFIW

ST6GAL2

401

Q96JF0
EPLPLPFHQWFLKNY

SH3TC2

236

Q8TF17
YWDFQFPHPLLPNVE

UGT2B4

261

P06133
PETPKWFHLPYLFQM

FCMR

136

O60667
LNPVWPAKPFHFQIS

PLCG1

1136

P19174
APLFLPQHHFLWYVK

PLEKHH1

926

Q9ULM0
WNFKFPHPFLPNVDF

UGT2B10

261

P36537
SWNFQFPYPLLPNVD

UGT2B7

261

P16662